 Beta predicts survival primary systemic amyloidosis PURPOSE study beta levels survival response patients primary systemic amyloidosis multiple myeloma PATIENTS METHODS study group untreated patients biopsy-proven primary systemic amyloidosis Mayo Clinic No patient multiple myeloma minimum follow-up patients years patient follow-up RESULTS median survival patients beta level months patients normal beta level equal micrograms/mL mumol/L months multivariate proportional-hazards model model congestive heart failure increased beta levels adjustment presence congestive heart failure beta level significant analysis patients normal renal function median survival elevated beta level months months normal level serum level beta patients nephrotic-range proteinuria renal insufficiency CONCLUSION serum beta level patients primary systemic amyloidosis useful objective factor subsets patients disease unfavorable outcomes